These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9674043

  • 21. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M.
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [Abstract] [Full Text] [Related]

  • 22. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
    Warabi Y, Matsumoto Y, Hayashi H.
    J Neurol Sci; 2007 Jan 15; 252(1):57-61. PubMed ID: 17125797
    [Abstract] [Full Text] [Related]

  • 23. [Interferon -beta therapy in multiple sclerosis].
    Satoh J.
    Nihon Rinsho; 2006 Jul 15; 64(7):1297-309. PubMed ID: 16838648
    [Abstract] [Full Text] [Related]

  • 24. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR.
    Arch Neurol; 2008 Mar 15; 65(3):337-44. PubMed ID: 18195134
    [Abstract] [Full Text] [Related]

  • 25. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr 15; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 26. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A.
    Arch Neurol; 2005 Apr 15; 62(4):563-8. PubMed ID: 15824253
    [Abstract] [Full Text] [Related]

  • 27. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
    Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP.
    Ann Neurol; 1999 Feb 15; 45(2):247-50. PubMed ID: 9989628
    [Abstract] [Full Text] [Related]

  • 28. Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
    Oger J, Gibbs E.
    Nat Clin Pract Neurol; 2006 Feb 15; 2(2):76-7. PubMed ID: 16932528
    [No Abstract] [Full Text] [Related]

  • 29. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B, Cepok S, Nessler S, Sommer N.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():23-8. PubMed ID: 11603112
    [Abstract] [Full Text] [Related]

  • 30. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N, Kraus J, Bauer R, Engelhardt B, Bregenzer T, Kuehne BS, Tofighi J, Laske C, Stolz E, Blaes F, Voigt K, Traupe H, Kaps M, Oschmann P.
    Acta Neurol Scand; 2004 Dec 15; 110(6):377-85. PubMed ID: 15527450
    [Abstract] [Full Text] [Related]

  • 31. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
    Moreira MA, Lana-Peixoto MA, Callegaro D, Haussen SR, Gama PD, Gabbai AA, Rocha FC, Lino AM, Participantes da Reunião do Consenso Expandido sobre Tratamento da Esclerose Múltipla do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla (BCTRIMS).
    Arq Neuropsiquiatr; 2002 Sep 15; 60(3-B):875-80. PubMed ID: 12364966
    [Abstract] [Full Text] [Related]

  • 32. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H, Kayes N, McPherson K.
    N Z Med J; 2006 Apr 21; 119(1232):U1939. PubMed ID: 16633398
    [Abstract] [Full Text] [Related]

  • 33. [Recent progress in treatment for multiple sclerosis].
    Kira J.
    Rinsho Shinkeigaku; 2000 Dec 21; 40(12):1261-3. PubMed ID: 11464473
    [Abstract] [Full Text] [Related]

  • 34. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 21; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 35. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients.
    Martínez A, de las Heras V, Mas Fontao A, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R.
    J Neuroimmunol; 2006 Apr 21; 173(1-2):196-9. PubMed ID: 16430971
    [Abstract] [Full Text] [Related]

  • 36. [Ensuring the long-term effectiveness of MS treatment].
    Krankenpfl J; 2005 Apr 21; 43(7-10):235. PubMed ID: 16515305
    [No Abstract] [Full Text] [Related]

  • 37. Can blood gene expression predict which patients with multiple sclerosis will respond to interferon?
    Kaminski N, Achiron A.
    PLoS Med; 2005 Feb 21; 2(2):e33; quiz e51. PubMed ID: 15736992
    [Abstract] [Full Text] [Related]

  • 38. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R, Stürzebecher CS, Kapp JF.
    Funct Neurol; 2001 Feb 21; 16(2):117-28. PubMed ID: 11495417
    [No Abstract] [Full Text] [Related]

  • 39. [Multiple sclerosis: the recent progress of research and treatment].
    Murai H, Kira J.
    Nihon Rinsho; 2001 Jun 21; 59(6):1211-8. PubMed ID: 11411138
    [Abstract] [Full Text] [Related]

  • 40. [Multiple sclerosis physiopathology].
    Créange A.
    Soins; 2009 Nov 21; (740):32-5. PubMed ID: 20014530
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.